Bacterial natural products (NPs) and their analogs constitute more than half of the new small molecule drugs developed over the past few decades. Despite this success, interest in natural products from major pharmaceutical companies has decreased even as genomics has uncovered the large number of biosynthetic gene clusters (BGCs) that encode for novel natural products. To date, there is still a lack of universal strategies and enabling technologies to discover natural products at scale and speed. This review highlights several of the opportunities provided by genome sequencing and bioinformatics, challenges associated with translating genomes into natural products, and examples of successful strain prioritization and BGC activation strategies that have been used in the genomic era for natural product discovery from cultivatable bacteria.

中文翻译：

---

针对细菌基因组进行天然产物发现。

细菌天然产物（NP）及其类似物构成了过去几十年来开发的新型小分子药物的一半以上。尽管取得了这一成功，但即使基因组学发现了编码新的天然产物的大量生物合成基因簇（BGC），主要制药公司对天然产物的兴趣仍在下降。迄今为止，仍然缺乏通用策略和使技术能够大规模和快速地发现天然产物的方法。这篇综述重点介绍了由基因组测序和生物信息学提供的一些机会，与将基因组转化为天然产物相关的挑战，以及成功的菌株优先级划分和BGC激活策略的实例，这些实例已在基因组时代用于从可培养细菌中发现天然产物。